TB-500 and the Analytical Record
TB-500 is the acetylated 17-23 fragment of thymosin beta-4, and its clearest literature is not clinical but analytical: the chemistry papers that pinned down what the compound actually is.
02 / TB-500
Available as VION
| Sequence | Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ) |
|---|---|
| Formula | C38H68N10O14 |
| Class | Thymosin Beta-4 active fragment |
TB-500 isolates the primary active fragment of Thymosin Beta-4, a protein found in blood platelets and wound fluid. Using only the low-molecular-weight active domain, research examines tissue permeability without the structural resistance of the full protein.
Studies observed TB-500 acting as a G-actin binding molecule, a mechanism examined in relation to cellular structure remodelling and the migration of keratinocytes and endothelial cells in tissue models.
In vascular assay models, research examined TB-500 in connection with endothelial differentiation and capillary network formation.
Trauma models have examined its relationship to localised inflammatory parameters, scar tissue formation, and programmed cell death cascades.
Library
TB-500 is the acetylated 17-23 fragment of thymosin beta-4, and its clearest literature is not clinical but analytical: the chemistry papers that pinned down what the compound actually is.
TB-500 is Ac-LKKTETQ, a seven-residue acetylated fragment corresponding to residues 17 to 23 of thymosin beta-4. Thymosin beta-4 is a 43-residue protein. Analytical chemists established the distinction in 2012, and it governs how the literature should be read.
For research purposes only. Not for human or veterinary consumption. Not for use in diagnostic, therapeutic, or clinical procedures.